title: Bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration: a double blind controlled study.
abstract: Fifty patients with corneal dendritic ulceration were randomly entered into a double blind clinical trial comparing BVDU eyedrops with TFT eyedrops. Of those receiving TFT 100% healed in a mean time of 6.7 days, while 92% of those receiving BVDU healed in a mean time of 8.7 days. There was no statistical difference between the two groups in terms of numbers healed, but BVDU was significantly slower in terms of days to heal. After a mean follow-up period of 7.5 months there has been one recurrence in each group.
authors.affiliation: Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
authors.forename: W J
authors.initials: WJ
authors.lastname: Power
authors.forename: A
authors.initials: A
authors.lastname: Benedict-Smith
authors.forename: M
authors.initials: M
authors.lastname: Hillery
authors.forename: K
authors.initials: K
authors.lastname: Brady
authors.forename: L M
authors.initials: LM
authors.lastname: Collum
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D003320:Corneal Ulcer / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D014271:Trifluridine / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; C020235:brivudine; D001973:Bromodeoxyuridine; D014271:Trifluridine